Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 4/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
| ▸ | DGKA | P23743 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25670236 | 1.00 | CYP3A4 (0.56) | CYP3A4TSHRATMTDP1LMNA | |
| SCHEMBL18202072 | 1.00 | CYP3A4 (0.56) | CYP3A4TSHRATMTDP1LMNA | |
| SCHEMBL25670246 | 1.00 | CYP3A4 (0.56) | CYP3A4TSHRATMTDP1LMNA | |
| SCHEMBL26356022 | 1.00 | CYP3A4 (0.56) | CYP3A4TSHRATMTDP1LMNA | |
| SCHEMBL18804786 | 1.00 | CYP3A4 (0.56) | CYP3A4TSHRATMTDP1LMNA | |
| SCHEMBL24314127 | 1.00 | CYP3A4 (0.56) | CYP3A4TSHRATMTDP1LMNA | |
| SCHEMBL21478864 | 1.00 | CYP3A4 (0.56) | CYP3A4TSHRATMTDP1LMNA | |
| SCHEMBL21478863 | 1.00 | CYP3A4 (0.56) | CYP3A4TSHRATMTDP1LMNA | |
| SCHEMBL20627951 | 1.00 | CYP3A4 (0.56) | CYP3A4TSHRATMTDP1LMNA | |
| SCHEMBL18804800 | 1.00 | CYP3A4 (0.56) | CYP3A4TSHRATMTDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325492-A1 | IONIZABLE LIPIDS, LIPID NANOPARTICLES FOR MRNA DELIVERY AND METHODS OF MAKING THE SAME | UNIVERSITY OF CINCINNATI (US) | 2025-10-23 | — | — | US | disclosed |
| US-20240238438-A1 | CD-90 Targeted Lipid Nanoparticles | FRED HUTCHINSON CANCER CENTER | 2024-07-18 | — | — | US | disclosed |
| US-20240238438-A1 | CD-90 Targeted Lipid Nanoparticles | FRED HUTCHINSON CANCER CENTER | 2024-07-18 | — | — | US | disclosed |
| US-20240226132-A1 | RNA COMPOSITIONS COMPRISING A BUFFER SUBSTANCE AND METHODS FOR PREPARING, STORING AND USING THE SAME | BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) | 2024-07-11 | — | — | US | disclosed |
| US-20240226132-A1 | RNA COMPOSITIONS COMPRISING A BUFFER SUBSTANCE AND METHODS FOR PREPARING, STORING AND USING THE SAME | BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) | 2024-07-11 | — | — | US | disclosed |
| WO-2024124143-A2 | HSC TARGETED LNP FOR DELIVERY OF PRO-APOPTOTIC MRNA AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024112882-A1 | TARGETED DELIVERY OF GENE EDITING CONSTRUCTS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024063789-A9 | COMPOSITIONS FOR DELIVERY OF MALARIA ANTIGENS AND RELATED METHODS | BioNTech SE (DE) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024086614-A2 | TARGETED LNP-MRNA WITH MINIMAL OFF-TARGET EXPRESSION AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024083345-A1 | METHODS AND USES ASSOCIATED WITH LIQUID COMPOSITIONS | BioNTech SE (DE) | 2024-04-25 | — | — | WO | disclosed |
| WO-2018107026-A1 | DELIVERY OF TARGET SPECIFIC NUCLEASES | SANGAMO THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018081480-A1 | LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018078053-A1 | LIPID NANOPARTICLE MRNA VACCINES | CUREVAC AG (DE) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018081638-A1 | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20170283367-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2017-10-05 | — | — | US | disclosed |
| US-20170283367-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2017-10-05 | — | — | US | disclosed |
| US-20170119904-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2017-05-04 | — | — | US | disclosed |
| US-20170119904-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2017-05-04 | — | — | US | disclosed |
| WO-2017075531-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2017-05-04 | — | — | WO | disclosed |
| WO-2016176330-A1 | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283367-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | HNRNPA2B1, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP3A4 4215/4885TSHR 657/4885ATM 3573/4885 |
| US-20170119904-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | PHOSPHO1, LPAR1, NPC1 | CYP3A4 3989/4885TSHR 1707/4885ATM 3554/4885 |
| US-20240238438-A1 | CD-90 Targeted Lipid Nanoparticles | CD63, CD99, LY96 | CYP3A4 4571/4885TSHR 2124/4885ATM 4666/4885 |
| US-20250325492-A1 | IONIZABLE LIPIDS, LIPID NANOPARTICLES FOR MRNA DELIVERY AND METHODS OF MAKING THE SAME | LIPA, CETP, ABCB4 | CYP3A4 2450/4885TSHR 2934/4885ATM 4738/4885 |
| US-20240226132-A1 | RNA COMPOSITIONS COMPRISING A BUFFER SUBSTANCE AND METHODS FOR PREPARING, STORING AND USING THE SAME | SNRPB2, NSUN2, RNMT | CYP3A4 4854/4885TSHR 4465/4885ATM 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.